393 related articles for article (PubMed ID: 24379682)
1. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
Chen X; Soma LA; Fromm JR
Onco Targets Ther; 2013 Dec; 7():45-56. PubMed ID: 24379682
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Vaklavas C; Forero-Torres A
Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
[TBL] [Abstract][Full Text] [Related]
3. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
5. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
Agrusa JE; Egress ER; Lowe EJ
Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD30 Antibodies for Hodgkin lymphoma.
Foyil KV; Bartlett NL
Curr Hematol Malig Rep; 2010 Jul; 5(3):140-7. PubMed ID: 20446121
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin.
van de Donk NW; Dhimolea E
MAbs; 2012; 4(4):458-65. PubMed ID: 22684302
[TBL] [Abstract][Full Text] [Related]
12. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
14. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.
Siddiqi T; Thomas SH; Chen R
Pharmgenomics Pers Med; 2014; 7():79-85. PubMed ID: 24672256
[TBL] [Abstract][Full Text] [Related]
15. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
[TBL] [Abstract][Full Text] [Related]
16. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies.
Han TH; Chen R; Advani R; Berryman RB; Smith SE; Forero-Torres A; Rosenblatt JD; Smith MR; Zain J; Hunder NN; Engert A
Cancer Chemother Pharmacol; 2013 Jul; 72(1):241-9. PubMed ID: 23719719
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.
Donato EM; Fernández-Zarzoso M; Hueso JA; de la Rubia J
Onco Targets Ther; 2018; 11():4583-4590. PubMed ID: 30122950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
